Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.

Details

Language :

English

ISSN :

20406207

Volume :

14

Database :

Complementary Index

Journal :

Therapeutic Advances in Hematology

Publication Type :

Academic Journal

Accession number :

175137758

Full Text :

https://doi.org/10.1177/20406207231173489